Cargando…
SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and functio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798727/ https://www.ncbi.nlm.nih.gov/pubmed/36581908 http://dx.doi.org/10.1186/s13058-022-01596-y |
_version_ | 1784860964837916672 |
---|---|
author | Luo, Juan Zou, Hailin Guo, Yibo Tong, Tongyu Ye, Liping Zhu, Chengming Deng, Liang Wang, Bo Pan, Yihang Li, Peng |
author_facet | Luo, Juan Zou, Hailin Guo, Yibo Tong, Tongyu Ye, Liping Zhu, Chengming Deng, Liang Wang, Bo Pan, Yihang Li, Peng |
author_sort | Luo, Juan |
collection | PubMed |
description | Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction. |
format | Online Article Text |
id | pubmed-9798727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97987272022-12-30 SRC kinase-mediated signaling pathways and targeted therapies in breast cancer Luo, Juan Zou, Hailin Guo, Yibo Tong, Tongyu Ye, Liping Zhu, Chengming Deng, Liang Wang, Bo Pan, Yihang Li, Peng Breast Cancer Res Review Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction. BioMed Central 2022-12-29 2022 /pmc/articles/PMC9798727/ /pubmed/36581908 http://dx.doi.org/10.1186/s13058-022-01596-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Luo, Juan Zou, Hailin Guo, Yibo Tong, Tongyu Ye, Liping Zhu, Chengming Deng, Liang Wang, Bo Pan, Yihang Li, Peng SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title | SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title_full | SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title_fullStr | SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title_full_unstemmed | SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title_short | SRC kinase-mediated signaling pathways and targeted therapies in breast cancer |
title_sort | src kinase-mediated signaling pathways and targeted therapies in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798727/ https://www.ncbi.nlm.nih.gov/pubmed/36581908 http://dx.doi.org/10.1186/s13058-022-01596-y |
work_keys_str_mv | AT luojuan srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT zouhailin srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT guoyibo srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT tongtongyu srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT yeliping srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT zhuchengming srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT dengliang srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT wangbo srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT panyihang srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer AT lipeng srckinasemediatedsignalingpathwaysandtargetedtherapiesinbreastcancer |